Did You Know...
...that after Parker Brothers executives turned down the game of Monopoly because it had "52 fundamental errors" (including taking too long to play), a copy of the game wound up in the home of the company president who stayed up until 1 a.m. to finish playing it? He was so impressed by the game that the next day he wrote to inventor Charles Darrow and offered to buy it!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120040431 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of o... | 02/16/2012 |
| 20120029167 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND A drug using the magnetic properties of a metal salen complex as represented by the following general formula in order to magnetize the intended drug by chemically binding the drug to a metal salen complex so that the drug can be delivered to the target diseased site. T... | 02/02/2012 |
| 20110288041 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q... | 11/24/2011 |
| 20110275586 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q... | 11/10/2011 |
| 20110218168 | SUBSTITUTED POLYAMINES AS INHIBITORS OF BACTERIAL EFFLUX PUMPS Disclosed are methods of treating bacterial infections including those caused by multidrug resistant bacteria using polyamine efflux pump inhibiting compounds, including for example N-benzylated polyazaalkanes, N-benzylated polyaminoalkanes, or mixed N-benzylated poly(a... | 09/08/2011 |
| 20110136752 | NOVEL ANTIBIOTICS The invention relates generally to novel antibiotics and their analogs, to processes for the preparation of these novel antibiotics, to pharmaceutical compositions comprising the novel antibiotics; and to methods of using the novel antibiotics to treat or inhibit variou... | 06/09/2011 |
| 20110118202 | Molecules which Bind to the Dimerization Initiation Site (DIS) of HIV RNA, Their Synthesis and Their Applications as Drugs The dimerization of HIV RNA is a key step in the virus replication cycle. Based on RNA DIS crystal structures, a novel kind of compounds, dimeric or not, based on neamine was designed and synthesized. Biological studies showed that such compounds bind and interfere with... | 05/19/2011 |
| 20110098239 | NOVEL DIARYL HEPATONOID-BASED COMPOUNDS AND USE THEREOF The present invention relates to a diaryl hepatonoid-based compound of formula (1) having viral inhibitory activity; its pharmaceutically acceptable salt; or a hydrate, a solvate or a prodrug of any of the foregoing, and a pharmaceutical composition comprising the same,... | 04/28/2011 |
| 20110003980 | Oligo-Aminosaccharide compound An oligo-aminosaccharide compound formed by binding 3 to 6 saccharides, such as 2,6-diamino-2,6-dideoxy-α-(1→4)-D-glucopyranose oligomers, or a salt thereof, which has high affinity to a double-stranded nucleic acid.... | 01/06/2011 |
| 20100292179 | TARGET We describe the functional cloning and the use of a non-fungal inositol phosphoryceraminde synthase (IPC synthase) in a screening assay for the identification of agents that target and antagonize the activity of IPC synthase.... | 11/18/2010 |
| 20100286031 | Antibiotic Formulations, Unit Doses, Kits and Methods An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present... | 11/11/2010 |
| 20100273726 | METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS ACTIVE METABOLITES ISOLATED FROM LAURUS NOBILIS AND COMBINATIONS THEREOF This present provides kaempferol-3-(2-E,3-Z-di-p-coumaroyl)-rhamnoside, kaempferol-3-(2-Z-3-E-di-p-coumaroyl)-rhamnoside, and kaempferol-3-(2,3-di-Z-p-coumaroyl)-rhamnoside compounds useful as a new class of anti-bacterial agents. These compounds are extracted from P... | 10/28/2010 |
| 20100086973 | GLYCOSYLATE DERIVATIVES OF MITHRAMYCIN, METHOD OF PREPARATION AND USES THEREOF The present invention provides compounds characterized by the formula (I), where each of the substituent radicals is described in the specification. The invention also describes the use of said compounds in the treatment of various diseases, including: cancer or tumoral... | 04/08/2010 |
| 20090312530 | Processes for the convergent synthesis of calicheamicin derivatives This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.... | 12/17/2009 |
| 20090288658 | Antibiotic Formulations, Unit Doses, Kits, and Methods An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present... | 11/26/2009 |
| 20090209744 | Antibacterial agent and therapeutic agent for Johne's disease containing the same An antibacterial agent having high antibacterial activity against Mycobacterium avium subsp. paratuberculosis is provided. Specifically, the antibacterial agent of the present invention having high antibacterial activity against Mycobacterium avium ... | 08/20/2009 |
| 20090069220 | DNA-BINDING POLYAMIDE DRUG CONJUGATES A conjugate of formula:
... | 03/12/2009 |
| 20090023665 | ANTIBIOTICS GE 81112 FACTORS A, B, B1, PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS, AND USE THEREOF The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compos... | 01/22/2009 |
| 20080300199 | ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.... | 12/04/2008 |
| 20080227963 | Process for preparing glycopeptide phosphonate derivatives Disclosed are processes for preparing glycopeptide phosphonate derivatives having an amino-containing side chain. Several of the process steps are conducted in a single reaction vessel without isolation of intermediate reaction products, thereby generating less waste an... | 09/18/2008 |
| 20070224635 | Regulated Stop Codon Readthrough Methods for screening or selecting cells expressing a polypeptide of interest, e.g. for selecting cells expressing a desired level of a polypeptidé of interest, for evaluating recombinant polypeptide expression in a population of cells, or for selecting cells expressin... | 09/27/2007 |
| 20070203081 | AMINOGLYCOSIDES AS ANTIBIOTICS The present invention provides aminoglycosides and pharmaceutical compositions that include the aminoglycosides. The aminoglycosides are useful to treat or prevent infectious diseases (e.g., bacterial infections) in a mammal (e.g., human). ... | 08/30/2007 |
| 20070203080 | New Drug Delivery System for Crossing the Blood Brain Barrier New ubiquinol analogs are disclosed, as well as methods of using these compounds to deliver drug moieties to the body. ... | 08/30/2007 |
| 20070185040 | Guanidinium derivatives for improved cellular transport Reagents and methods useful for the synthesis of conjugates comprising guanidinylated cyclic acetals are provided. Also provided are methods for increasing the cellular uptake of various therapeutic compounds and treatment modalities using these conjugates. ... | 08/09/2007 |
| 20070161581 | Novel aminoglycoside antibiotics effective against methicillin resistant staphylococcus auerus (mrsas) Disclosed are compounds represented by general formula (I) or pharmacologically acceptable salts or solvates thereof having excellent antimicrobial activity against bacteria causative of severe infections such as pneumonia and septicemia, particularly against MRSA, and... | 07/12/2007 |
| 20070054870 | Heterobifunctional pan-selectin inhibitors Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediate... | 03/08/2007 |
| 20060286065 | Releasable polymeric conjugates based on aliphatic biodegradable linkers Activated polymeric bicine derivatives such as as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed. ... | 12/21/2006 |
| 20060234961 | Novel anti bacterial compounds The invention relates to novel paranmycin compounds that have activity against gram positive and gram negative bacteria, preferably bacteria that are resistant to other antibiotics. Paranmycins are of the general formula ... | 10/19/2006 |
| 20060105941 | Mixed antibiotic codrugs Novel compounds which degrade in vivo into two or more different active antibiotics are disclosed herein. Methods, compositions, and medicaments related thereto are also disclosed. ... | 05/18/2006 |
| 20050272674 | Preparation method of valienamine from acarbose and/or acarbose derivatives using trifluoroacetic acid The present invention provides a preparation method of valienamine from acarbose or acarbose derivatives using organic acid TFA (trifluoroacetic acid). By using the method of the present invention, valienamine, the core precursor of voglibose which is a strong retardant... | 12/08/2005 |
| 20050239725 | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily am... | 10/27/2005 |
| 20050192236 | Crystaline clindamycin free base The antibiotic drug clindamycin is provided as a crystalline free base. Three polymorphic/pseudopolymorphic forms of crystalline clindamycin free base are disclosed. Also provided are pharmaceutical compositions comprising crystalline clindamycin free base. Processes fo... | 09/01/2005 |
| 20050171035 | Aminoglycosides as antibiotics The present invention provides aminoglycosides and pharmaceutical compositions that include the aminoglycosides. The aminogylcosides are useful to treat or prevent infectious diseases (e.g., bacterial infections) in a mammal (e.g., human). ... | 08/04/2005 |
| 20050090462 | Aminoglycoside antibiotics and methods of using same The present invention relates to aminoglycoside compounds having antibiotic activity. Moreover, the present invention relates to L-aminoglycoside compounds and diastereomers thereof which posses antibiotic activity and are not susceptible to development of resistant bac... | 04/28/2005 |
| 20050020514 | Antibiotics ge 81112 factors a,b.b1, pharmaceutically acceptable salts and compositions, and use thereof The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compos... | 01/27/2005 |
| 20050004052 | Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes A novel group of aminoglycosides which share some structural features of currently available aminoglycosides with regard to the backbone, while also having significant structural differences. The similarity enables these aminoglycosides to be highly potent and effective... | 01/06/2005 |
